Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195

Leukemia volume 17, pages 314–318 (2003)Cite this article

Abstract

HuM195 is a humanized, unconjugated, anti-CD33 monoclonal antibody. Fifty adult patients with relapsed or refractory AML were randomized to receive HuM195 at a dose of 12 or 36 mg/m2 by intravenous infusion over 4 h on days 1–4 and 15–18. Patients with stable or responding disease received two additional cycles on days 29–32 and 43–46. HuM195 was given as first salvage therapy in 24 patients and as second or subsequent salvage therapy in 26 patients. Pretreatment blast percentage in the marrow was between 5 and 30% in 20 patients with the others having blast counts greater than 30%. The median age of patients was 62 years (range 26–86) and CD33 was detected in 95% of patients for whom immunophenotyping was available. Of 49 evaluable patients, two complete and one partial remission were observed. All three responses were in patients treated at the 12 mg/m2 dose level and all had baseline blast percentages less than 30%. Decreases in blast counts ranging from 30 to 74% were seen in nine additional patients. Infusion-related events of fever and chills occurred in the majority of patients and were generally mild and primarily related to the first dose of antibody. No hepatic, renal or cardiac toxicities were observed and other adverse events such as nausea, vomiting, mucositis and diarrhea were uncommon or felt to be unrelated to HuM195. In addition, anti-HuM195 responses were not detected. HuM195 as a single agent has minimal, but observable, anti-leukemic activity in patients with relapsed or refractory AML and activity is confined to patients with low burden disease. No significant differences in clinical efficacy or toxicity were seen between the two dose levels of antibody. HuM195 was well tolerated with infusion-related fevers and chills the predominant toxicities seen. Meaningful clinical efficacy of this unconjugated monoclonal antibody may be realized only in patients with minimal residual disease, or in combination with chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Zittoun R . Chemotherapy of acute myelogenous leukemia. A review. Leukemia 1992; 6 (Suppl. 2), 36–38.

    PubMed  Google Scholar 

  2. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield C . Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997; 24: 17–31.

    CAS  PubMed  Google Scholar 

  3. Estey E, Thall P, David C . Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 1997; l 40 (Suppl.): S9–12.

    Article  Google Scholar 

  4. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin R . Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7: 1637–1645.

    Article  CAS  PubMed  Google Scholar 

  5. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, Zittoun R, Casadevall N, Marie JP . The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870–877.

    CAS  PubMed  Google Scholar 

  6. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ . Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 1989; 3: 339–348.

    CAS  PubMed  Google Scholar 

  7. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD . Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 1989; 3: 440–445.

    CAS  PubMed  Google Scholar 

  8. McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA . Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother 1994; 39: 367–374.

    Article  CAS  PubMed  Google Scholar 

  9. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS . A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478–490.

    Article  CAS  PubMed  Google Scholar 

  10. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ . Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294–303.

    Article  CAS  PubMed  Google Scholar 

  11. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA . Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761–6767.

    CAS  PubMed  Google Scholar 

  12. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ . A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83: 1760–1768.

    CAS  PubMed  Google Scholar 

  13. Xu Y, Scheinberg DA . Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin Cancer Res 1995; 1: 1179–1187.

    CAS  PubMed  Google Scholar 

  14. Caron PC, Dumont L, Scheinberg DA . Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998; 4: 1421–1428.

    CAS  PubMed  Google Scholar 

  15. Willman CL . The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 1997; 34: 25–33.

    CAS  PubMed  Google Scholar 

  16. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, Hall AG . The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994; 88: 105–109.

    Article  CAS  PubMed  Google Scholar 

  17. Caron PC, Lai LT, Scheinberg DA . Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1995; 1: 63–70.

    CAS  PubMed  Google Scholar 

  18. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK . Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66–73.

    CAS  PubMed  Google Scholar 

  19. Gianni L . Tolerability in patients receiving trastuzumab with or without chemotherapy. Ann Oncol 2001; 12 (Suppl. 1): S63–S68.

    Article  PubMed  Google Scholar 

  20. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA . Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372–380.

    CAS  PubMed  Google Scholar 

  21. Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, Pitto A, Bacigalupo A, Moretta L, Mingari MC . Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci USA 2001; 98: 5764–5769.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Mingari MC, Vitale C, Romagnani C, Falco M, Moretta L . p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunol Rev 2001; 181: 260–268.

    Article  CAS  PubMed  Google Scholar 

  23. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, New York Medical College, Valhalla, NY, USA

    E Feldman & K Seiter

  2. Department of Hematology and Medical Oncology, The Cleveland Clinic, Cleveland, OH, USA

    M Kalaycio

  3. Holden Comprehensive Cancer Center and the Department of Internal Medicine, University of Iowa, Iowa City, IA, USA

    G Weiner

  4. Division of Hematology/Oncology, Vincent T Lombardi Cancer Research Center, Washington, DC, USA

    S Frankel

  5. Don Monti Division of Oncology, North Shore University Hospital, Manhasset, NY, USA

    P Schulman

  6. The West Clinic, PC, Memphis, TN, USA

    L Schwartzberg

  7. Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    J Jurcic & D Scheinberg

  8. Department of Medicine, Hematology-Medical Oncology Section, University of Puerto Rico School of Medicine, San Juan, PR, USA

    E Velez-Garcia

  9. Protein Design Labs, Inc., Fremont, CA, USA

    D Levitt & N Wedel

Authors
  1. E Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Weiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Frankel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Schulman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Schwartzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Jurcic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Velez-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Seiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Levitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N Wedel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldman, E., Kalaycio, M., Weiner, G. et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 17, 314–318 (2003). https://doi.org/10.1038/sj.leu.2402803

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402803

Keywords

This article is cited by

Search

Advanced search

Quick links